- Home
- LUCY vs TNXP Comparison
LUCY vs TNXP Comparison
Compare LUCY & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCY
- TNXP
- Stock Information
- Founded
- LUCY 2017
- TNXP 2007
- Country
- LUCY United States
- TNXP United States
- Employees
- LUCY N/A
- TNXP N/A
- Industry
- LUCY Ophthalmic Goods
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- LUCY Health Care
- TNXP Health Care
- Exchange
- LUCY Nasdaq
- TNXP Nasdaq
- Market Cap
- LUCY 18.5M
- TNXP 19.5M
- IPO Year
- LUCY 2022
- TNXP N/A
- Fundamental
- Price
- LUCY $5.55
- TNXP $0.37
- Analyst Decision
- LUCY Strong Buy
- TNXP Strong Buy
- Analyst Count
- LUCY 1
- TNXP 2
- Target Price
- LUCY $20.00
- TNXP $53.50
- AVG Volume (30 Days)
- LUCY 53.0K
- TNXP 186.1M
- Earning Date
- LUCY 11-12-2024
- TNXP 11-12-2024
- Dividend Yield
- LUCY N/A
- TNXP N/A
- EPS Growth
- LUCY N/A
- TNXP N/A
- EPS
- LUCY N/A
- TNXP N/A
- Revenue
- LUCY $1,561,506.00
- TNXP $11,291,000.00
- Revenue This Year
- LUCY $68.16
- TNXP $62.53
- Revenue Next Year
- LUCY $636.84
- TNXP $26.17
- P/E Ratio
- LUCY N/A
- TNXP N/A
- Revenue Growth
- LUCY 158.62
- TNXP 183.05
- 52 Week Low
- LUCY $3.26
- TNXP $0.12
- 52 Week High
- LUCY $27.20
- TNXP $21.76
- Technical
- Relative Strength Index (RSI)
- LUCY 37.26
- TNXP 62.63
- Support Level
- LUCY $5.74
- TNXP $0.18
- Resistance Level
- LUCY $6.61
- TNXP $1.30
- Average True Range (ATR)
- LUCY 0.51
- TNXP 0.11
- MACD
- LUCY -0.07
- TNXP 0.02
- Stochastic Oscillator
- LUCY 0.00
- TNXP 17.41
About LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products Lucyd Lyte glasses enable the wearer to listen to music, take and make calls, and use voice assistants to perform many common smartphone tasks hands free.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.